BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

被引：0
|
作者：
Song, Erwei
Yao, Herui
Sun, Meili
Zong, Hong
Lin, Rongbo
Zou, Wen
Ding, Muran
Yu, Jing
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-04-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-04-03
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
    Gail D. Lewis
    Guangmin Li
    Jun Guo
    Shang-Fan Yu
    Carter T. Fields
    Genee Lee
    Donglu Zhang
    Peter S. Dragovich
    Thomas Pillow
    BinQing Wei
    Jack Sadowsky
    Douglas Leipold
    Tim Wilson
    Amrita Kamath
    Michael Mamounas
    M. Violet Lee
    Ola Saad
    Voleak Choeurng
    Alexander Ungewickell
    Sharareh Monemi
    Lisa Crocker
    Kevin Kalinsky
    Shanu Modi
    Kyung Hae Jung
    Erika Hamilton
    Patricia LoRusso
    Ian Krop
    Melissa M. Schutten
    Renee Commerford
    Mark X. Sliwkowski
    Eunpi Cho
    Nature Communications, 15
  • [32] A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors.
    Richards, Donald A.
    Braiteh, Fadi S.
    Garcia, A. A.
    Denlinger, Crystal Shereen
    Conkling, Paul R.
    Edenfield, William Jeffery
    Anthony, Stephen Patrick
    Hellerstedt, Beth A.
    Raju, Robert N.
    Becerra, Carlos
    Harb, Wael A.
    Smith, David A.
    McDonagh, Charlotte Fenton
    Kawash, Kate-Lyn
    Frye, Sasha
    Moyo, Victor M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study
    Wu, Jiong
    Zhang, Jian
    Du, Yiqun
    Zou, Wen
    Ding, Muran
    Yang, Hui
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin
    Zhu, Yi
    CANCER RESEARCH, 2024, 84 (09)
  • [34] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
    Zhang, Li
    Ma, Yuxiang
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Huang, Yan
    Yang, Yunpeng
    Chen, Likun
    Hou, Xue
    Zou, Wen
    Ding, Muran
    Yu, Jing
    Zhang, Suoyu
    Wang, Junxian
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
    Burris, Howard A., III
    Rugo, Hope S.
    Vukelja, Svetislava J.
    Vogel, Charles L.
    Borson, Rachel A.
    Limentani, Steven
    Tan-Chiu, Elizabeth
    Krop, Ian E.
    Michaelson, Richard A.
    Girish, Sandhya
    Amler, Lukas
    Zheng, Maoxia
    Chu, Yu-Waye
    Klencke, Barbara
    O'Shaughnessy, Joyce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 398 - 405
  • [36] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Richards, D.
    Braiteh, F.
    Anthony, S.
    Edenfield, W.
    Hellerstedt, B.
    Raju, R.
    Conkling, P.
    McDonagh, C.
    Frye, S.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
  • [38] Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors
    Miao, Zhenwei
    Lin, Fengjuan
    Rao, Xi
    Huang, Yong
    Wang, Feng
    Lu, Yao
    Huang, Xiuying
    Huang, Yunsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
    Lopez, Diana M.
    Barve, Minal
    Wang, Judy
    Bullock, Andrea J.
    Pectasides, Eirini
    Vaishampayan, Ulka
    Spira, Alexander I.
    Ulahannan, Susanna
    Patnaik, Amita
    Sanborn, Rachel E.
    Cicic, Dragan
    Ang, Qiuqing
    Bergonio, Gregory
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [40] RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies.
    Wang, Jiayu
    Liu, Yunjiang
    Zhang, Qingyuan
    Feng, Jifeng
    Fang, Jianmin
    Chen, Xuelian
    Han, Yiqun
    Li, Qing
    Zhang, Pin
    Yuan, Peng
    Ma, Fei
    Luo, Yang
    Fan, Ying
    Cai, Ruigang
    Chen, Shanshan
    Li, Qiao
    Li, Yiqun
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345